AZD1208 is primarily researched for its potential in cancer treatment, particularly in targeting specific pathways involved in the growth and survival of cancer cells. It is an inhibitor of PIM kinases, which are proteins that play a role in cell proliferation and apoptosis. By blocking these kinases, AZD1208 aims to hinder the progression of certain cancers, especially those resistant to conventional therapies. Its application is largely focused on preclinical and clinical studies to evaluate its efficacy and safety in treating hematologic malignancies and solid tumors. Researchers are also exploring its potential in combination with other anticancer agents to enhance therapeutic outcomes.